Showing posts with label pharmacy. Show all posts
Showing posts with label pharmacy. Show all posts

Wednesday, 20 April 2016

PubMed Update March 2016

23 this month.

McDonald R, Strang J.
Addiction. 2016 Mar 30. doi: 10.1111/add.13326. [Epub ahead of print] Review.
Comments: Take-home naloxone meets all Bradford Hill criteria for causality in reducing opioid overdose mortality. Incidence of fatality among overdoses in the setting of take-home naloxone was 0.8%.

Loreck D, Brandt NJ, DiPaula B.
J Gerontol Nurs. 2016 Apr 1;42(4):10-5. doi: 10.3928/00989134-20160314-04.
Comments: A review of the U.S. situation and treatments for opioid use disorder.

Darke S, Marel C, Mills KL, Ross J, Slade T, Tessson M.
Drug Alcohol Depend. 2016 May 1;162:206-10. doi: 10.1016/j.drugalcdep.2016.03.010. Epub 2016 Mar 18.
Comments: Heroin use is associated with 25-50 years of life lost. Over half of deaths and nearly two-thirds of years of life lost were due to opioid overdose.

Olsson MO, Bradvik L, Öjehagen A, Hakansson A.
Drug Alcohol Depend. 2016 May 1;162:176-81. doi: 10.1016/j.drugalcdep.2016.03.009. Epub 2016 Mar 17.
Comments: Accidental overdose death and suicide are distinct entities, with distinct predictive variables. This is important.

Saucier CD, Zaller N, Macmadu A, Green TC.
Drug Alcohol Depend. 2016 May 1;162:211-8. doi: 10.1016/j.drugalcdep.2016.03.011. Epub 2016 Mar 19.
Comments: Harm reduction programs training law enforcement, a critical step forward.

Levine M, Sanko S, Eckstein M.
Prehosp Emerg Care. 2016 Mar 28:1-4. [Epub ahead of print]
Comments: Studies of pre-hospital naloxone without transport to the hospital have uniformly shown extremely low rates of re-overdose or death in the ensuing 24 hours. This study examined 205 people over a much longer period and identified 3 deaths in the subsequent month. Again, this supports the relative safety of naloxone management and yet emphasizes the high risk of mortality in this population.

Lott DC, Rhodes J.
Am J Addict. 2016 Apr;25(3):221-6. doi: 10.1111/ajad.12364. Epub 2016 Mar 22.
Comments: Education is excellent, but providing the medication on-site is critical.

Kitch BB, Portela RC.
Prehosp Emerg Care. 2016 Mar-Apr;20(2):226-9. doi: 10.3109/10903127.2015.1076097.
Comments: Police administering naloxone in the setting of fentanyl overdoses.

Burns G, DeRienz RT, Baker DD, Casavant M, Spiller HA.
Clin Toxicol (Phila). 2016 Mar 21:1-4. [Epub ahead of print]
Comments: Fascinating article! Many of us have wondered why fentanyl is such an extreme problem when used illicitly. This paper describes the phenomenon of chest wall rigidity with rapid IV administration of fentanyl, a possible explanation for the high risk of death in the setting of increased illicit fentanyl availability.

Riley ED, Evans JL, Hahn JA, Briceno A, Davidson PJ, Lum PJ, Page K.
Am J Public Health. 2016 May;106(5):915-7. doi: 10.2105/AJPH.2016.303084. Epub 2016 Mar 17.
Comments: Increased use is associated with increased overdose. This has been a persistent finding, potentially in conflict with the findings that periods of abstinence are associated with overdose. That is to say, even though low tolerance is a risk for overdose, it seems that more regular rather than more sporadic use increases overdose risk. Prevention messaging on this topic remains challenging.

Frieden TR, Houry D.
N Engl J Med. 2016 Mar 15. [Epub ahead of print]
Comments: An editorial on the new CDC guidelines described below.

Dowell D, Haegerich TM, Chou R.
JAMA. 2016 Mar 15. doi: 10.1001/jama.2016.1464. [Epub ahead of print]
Comments: New guidelines for opioid prescribing that emphasize reliance upon other therapies first and limited doses of opioids. They do recommend use of opioid agonist treatments for patients with co-morbid chronic pain and opioid use disorder, such as buprenorphine which can be prescribed by general practitioners in the U.S., and co-prescription of naloxone to patients on higher doses (>50 morphine equivalent milligrams) or other risk factors.

McAuley A, Munro A, Bird SM, Hutchinson SJ, Goldberg DJ, Taylor A.
Drug Alcohol Depend. 2016 May 1;162:236-40. doi: 10.1016/j.drugalcdep.2016.02.031. Epub 2016 Mar 3.
Comments: Increased utilization but reduced likelihood of participants actually carrying naloxone on their person.

Dion KA.
J Addict Nurs. 2016 Jan-Mar;27(1):7-11. doi: 10.1097/JAN.0000000000000106.
Comments: Training nursing students in opioid overdose management.

Nielsen S, Van Hout MC.
Int J Drug Policy. 2016 Feb 15. pii: S0955-3959(16)30014-7. doi: 10.1016/j.drugpo.2016.02.006. [Epub ahead of print]
Comments: There’s some information out there but much more needed.


The next series of articles are all related to the lead author's (Dr Strang) belief that nasal naloxone is problematic; the final 5 being responses to the lead author’s recent article in Addiction critiquing nasal naloxone. Dr Strang has been a longtime advocate of naloxone, but not nasally administered. It’s important to note, as can be seen in the disclosures of his papers, that he/his employer hold a patent for buccal naloxone which is promoted in at least two of the papers (#17 & 18). I’ll withhold any further comments.

Strang J, McDonald R, Alqurshi A, Royall P, Taylor D, Forbes B.
Drug Alcohol Depend. 2016 Mar 9. pii: S0376-8716(16)00141-1. doi: 10.1016/j.drugalcdep.2016.02.042. [Epub ahead of print] Review.

Alqurshi A, Kumar Z, McDonald R, Strang J, Buanz A, Ahmed S, Allen E, Cameron P, Rickard JA, Sandhu V, Holt C, Stansfield R, Taylor D, Forbes B, Royall PG.
Mol Pharm. 2016 Mar 28. [Epub ahead of print]

Strang J, Mcdonald R.
Addiction. 2016 Apr;111(4):590-2. doi: 10.1111/add.13319. No abstract available.

Balster RL, Walsh SL.
Addiction. 2016 Apr;111(4):589-90. doi: 10.1111/add.13274. No abstract available.

Dale O.
Addiction. 2016 Apr;111(4):587-9. doi: 10.1111/add.13267. No abstract available.

Lobmaier PP, Clausen T.
Addiction. 2016 Apr;111(4):586-7. doi: 10.1111/add.13261. No abstract available.

Dietze P, Cantwell K.
Addiction. 2016 Apr;111(4):584-6. doi: 10.1111/add.13260. No abstract available.

Winstanley EL.
Addiction. 2016 Apr;111(4):583-4. doi: 10.1111/add.13255. No abstract available.


Tuesday, 22 March 2016

PubMed Update February 2016

Ten articles for February 2016.

[No authors listed]
ED Manag. 2016 Feb;28(2):13-9.
Comments: Review of the new CDC opioid prescribing guidelines.

Lenton SR, Dietze PM, Jauncey M.
Med J Aust. 2016 Mar 7;204(4):146-7. No abstract available.
Comments: Naloxone can now be over the counter in Australia, but there’s some work to be done in product design.

King R.
NASN Sch Nurse. 2016 Mar;31(2):96-101. doi: 10.1177/1942602X16628890.
Comments: Naloxone for school nurses in Delaware.

Agahi M, Shakoori V, Marashi SM.
Sultan Qaboos Univ Med J. 2016 Feb;16(1):e113-4. doi: 10.18295/squmj.2016.16.01.022. Epub 2016 Feb 2. No abstract available.
Comments: Long QT interval is a side effect of high methadone doses.


Ahlner J, Holmgren A, Jones AW.
Forensic Sci Int. 2016 Feb 3;265:138-143. doi: 10.1016/j.forsciint.2016.01.036. [Epub ahead of print]
Comments: Yet another population that may benefit from overdose prevention programming – persons arrested for impaired driving.

Jones CM, Lurie PG, Compton WM.
Am J Public Health. 2016 Apr;106(4):689-90. doi: 10.2105/AJPH.2016.303062. Epub 2016 Feb 18.
Comments: Some increase in sales; much of this increase may be accounted for by a selected number of programs. These data were also presented at the FDA meeting on naloxone in July 2015.


Butler MM, Ancona RM, Beauchamp GA, Yamin CK, Winstanley EL, Hart KW, Ruffner AH, Ryan SW, Ryan RJ, Lindsell CJ, Lyons MS.
Ann Emerg Med. 2016 Feb 10. pii: S0196-0644(15)01567-X. doi: 10.1016/j.annemergmed.2015.11.033. [Epub ahead of print]
Comments: 59% of opioid dependent participants were initially exposed via a medical prescription to them and 29% of those prescriptions came from emergency departments.

McLean K.
Int J Drug Policy. 2016 Mar;29:19-26. doi: 10.1016/j.drugpo.2016.01.009. Epub 2016 Jan 18.
Comments: This is fascinating. Poverty and social isolation.

Paulozzi LJ, Zhou C, Jones CM, Xu L, Florence CS.
Pharmacoepidemiol Drug Saf. 2016 Feb 10. doi: 10.1002/pds.3980. [Epub ahead of print]
Comments: Studying opioid prescribing is really complicated, because it involves making sense of – and trying to quantify – very complex and confusing medical decisions. This is an interesting analysis attempting to determine how much documentation of concerning opioid use behaviors results in changes in opioid prescribing.

Haug NA, Bielenberg J, Linder SH, Lembke A.
Subst Abus. 2016 Jan-Mar;37(1):35-41. doi: 10.1080/08897077.2015.1129390.

Comments: Naloxone-trained individuals on Twitter “had the highest optimism and the lowest amount of burnout and stigma.” 

Saturday, 5 September 2015

PubMed Update August 2015

Sixteen in August. Back on schedule (thanks to jetlag).

Hawk KF, Vaca FE, D'Onofrio G.
Yale J Biol Med. 2015 Sep 3;88(3):235-245. eCollection 2015 Sep. Review.
Comment: Can’t access full article. Appears to be a review of harm reduction strategies for opioid overdose prevention.

Brady KT, McCauley JL, Back SE.
Am J Psychiatry. 2015 Sep 4:appiajp201515020262. [Epub ahead of print]
Comment: Appropriately draws attention to the problem now faced in the United States: we are cutting back on opioid prescribing to try to limit further opioid dependence, but effectively abandoning many of the people who are already dependent.

DeVido J, Connery H, Hill KP.
J Opioid Manag. 2015 Jul-Aug;11(4):363-6. doi: 10.5055/jom.2015.0285.
Comment: Two case reports of sleep-disordered breathing among buprenorphine patients suggesting that buprenorphine may contribute to sleep apnea.

Paone D, Tuazon E, Stajic M, Sampson B, Allen B, Mantha S, Kunins H.
Drug Alcohol Depend. 2015 Aug 15. pii: S0376-8716(15)01598-7. doi: 10.1016/j.drugalcdep.2015.08.007. [Epub ahead of print]
Comment: Actually, none of the decedents tested positive for buprenorphine - very few (2) were found to have positive toxicology for norbuprenorphine, a metabolite demonstrating recent – but not recent enough to be causal – consumption of buprenorphine. This is not surprising since it’s tough to overdose on buprenorphine. Nice work.

Hassanian-Moghaddam H, Soltaninejad K, Shadnia S, Kabir A, Movahed M, Mirafzal A.
Basic Clin Pharmacol Toxicol. 2015 Aug 24. doi: 10.1111/bcpt.12476. [Epub ahead of print]
Comment: Lower consciousness/respirations once in the emergency room were associated with increased likelihood of being intubated and/or dying from methadone overdose. This is interesting in the context of previous papers included on this blog that demonstrate lower likelihood of such outcomes when naloxone is administered in the field. Is it time to think of naloxone as an automated electronic defibrillator?

Larance B, Lintzeris N, Bruno R, Peacock A, Cama E, Ali R, Kihas I, Hordern A, White N, Degenhardt L.
J Subst Abuse Treat. 2015 Jun 24. pii: S0740-5472(15)00137-3. doi: 10.1016/j.jsat.2015.06.001. [Epub ahead of print]
Comment: This is a complex population. Although risk outcomes appear closer to those of someone who uses heroin than those of someone prescribed opioids, the clinical characteristics overlap substantially with the latter group.


Jackson JL.
J Gen Intern Med. 2015 Aug 19. [Epub ahead of print] No abstract available.
Comment: Summarizes the Bingswanger paper and that’s about it.

Tucker D, Milloy MJ, Hayashi K, Nguyen P, Kerr T, Wood E.
Am J Addict. 2015 Sep;24(6):532-7. doi: 10.1111/ajad.12257. Epub 2015 Aug 18.
Comment: Really high-risk people inject methadone.

Evans E, Kelleghan A, Li L, Min J, Huang D, Urada D, Hser YI, Nosyk B.
Drug Alcohol Depend. 2015 Jul 17. pii: S0376-8716(15)00381-6. doi: 10.1016/j.drugalcdep.2015.07.010. [Epub ahead of print]
Comment: Some findings from a longitudinal study that I find hard to interpret and potentially specious.

Borriello R, Carfora A, Cassandro P, Petrella R.
Ann Clin Lab Sci. 2015 Jul;45(4):414-8.
Comment: The 6-MAM assay is pretty good.

Pirompanich P, Chankrachang S.
J Med Assoc Thai. 2015 Jul;98(7):703-8.
Comment: We’ve reviewed heroin-associated spongiform leukoencephalopathy before on this blog. This is another case identified in a heroin injector – instead of smoker – and review of the literature. Interestingly, this case was identified after an overdose.

Kiger ME, McCanta AC, Tong S, Schaffer M, Runciman M, Collins KK.
Pacing Clin Electrophysiol. 2015 Aug 8. doi: 10.1111/pace.12732. [Epub ahead of print]
Comment: There are some questions about the role of cardiac disease on overdose risk – this is pretty clearly the case for cocaine but not well understood for opioids. This report on WPW patients (WPW is an electrical conduction disease of the heart that affects repolarization of cardiac tissue and can result in potentially fatal arrhythmias in otherwise healthy people) refers briefly to a WPW patient who had to be resuscitated after methadone overdose. No further details unfortunately.

Green TC, Dauria EF, Bratberg J, Davis CS, Walley AY.
Harm Reduct J. 2015 Aug 6;12:25. doi: 10.1186/s12954-015-0058-x.
Comment: Two models of pharmacy provision of naloxone. Exciting work in New England.

LaBelle CT, Han SC, Bergeron A, Samet JH.
J Subst Abuse Treat. 2015 Jun 26. pii: S0740-5472(15)00146-4. doi: 10.1016/j.jsat.2015.06.010. [Epub ahead of print]
Comment: Describes an effort to expand buprenorphine treatment availability in Massachusetts.

Hassanian-Moghaddam H, Zamani N, Rahimi M, Shadnia S, Pajoumand A, Sarjami S.
Arch Iran Med. 2014 Aug;17(8):534-8. doi: 014178/AIM.003.
Comment: Interesting that pesticides match opioids as the two leading causes of poisoning death.

[No authors listed]
R I Med J (2013). 2014 Apr;97(4):49. No abstract available.
Comment: We should exercise caution in our use of the term “Narcan” in the future as the brand was purchased by the manufacturers of a nasal device that is likely to be approved in the near future. Promoting one brand over another is poor form in public health and academic venues.